Impact Investors Panel
Seeking Beyond Financial Returns
Tuesday (3/14) – 2 PM EDT
This panel make equity investments into early-stage companies and organizations with the intent to generate a positive social or environmental impact alongside a financial return. Some of these firms focus on impacting a specific patient population, whereas others have broader goals in creating an impact for their local region, or the world. Topics may include:
- What is impact investing?
- How is the investment mandate affected by the impact goal?
- How do investors measure and increase the impact of their capital?
- How should startups approach impact investors for fundraising, and what criteria do they use to evaluate opportunities?
- What separates an impact investor from a traditional VC?
Panelists will discuss how impact investors provide capital to address challenges in life sciences and healthcare sectors worldwide. While impact investing market is a relatively new trend, panelists will also discuss how companies can successfully fundraise from impact investors and the best way to develop a relationship with relevant investors.
Steve Curtis, Director, New Ventures, BrightEdge (Moderator)
Prior to joining ACS/BrightEdge, Steve managed MPM Capital’s Oncology Innovations Fund, a hybrid venture/philanthropy investment collaboration with Dana-Farber Cancer Institute. At MPM, he led the investments in seed and Series A stage biotech companies and held various interim operating roles in many of these start-ups. Steve also supported MPM’s partnership with a number of strategic investors.
Prior to joining MPM, Steve was Senior Director of Business Development for Eli Lilly and Company. In that role, he focused on Lilly’s limited partnerships in top-tier venture funds, direct equity investments and other “shared-risk” relationships with biotech companies. Prior to Lilly, Steve co-led the Bioscience Ventures group within 2M Companies, the Dallas-based family office of Morton H. Meyerson, focusing on early-stage private healthcare investments. Before 2M, he worked at Reata Pharmaceuticals, running the Technology Evaluation and In-Licensing program, where he led the in-licensing of an asset that is now in clinical development.
As a volunteer, Steve sits on the Allocation Advisory Board for the Follicular Lymphoma Foundation, the Advisory Committee for the IBD Ventures program for the Crohn’s & Colitis Foundation, and is an Expert Advisor for The Research Acceleration and Innovation Network (TRAIN) of the Milken Institute’s FasterCures division.
Caleb Bell, Venture Partner, Corundum Systems Biology
Caleb is an innovator, entrepreneur and investor with decades of experience building and investing in deep tech startups internationally. Caleb is a Venture Investor for Corundum Systems Biology (CSB), a Tokyo based innovation hub that is involved in early stage venture investing, sponsored research and directly undertaking fundamental research with the singular purpose to improve human wellbeing. Prior to his investing role with CSB, Caleb has worked for Arcline Investment Management, G4S Capital, Beyond Next Ventures, Prime Movers Lab and CTIC Capital successfully deploying around $500 million in life sciences transactions. Prior to his career as an investor, Caleb spent two decades managing businesses he founded across diverse industries including hospitality, biotech and financial services.